asenapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychoactive	4115	65576-45-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: Org-5222 Org 5222 asenapine saphris asenapine maleate sycrest	Molecular weight: 285.77 Formula: C17H16ClNO CLOGP: 4.28 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -3.96 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

Org-5222
Org 5222
asenapine
saphris
asenapine maleate
sycrest

Molecular weight: 285.77
Formula: C17H16ClNO
CLOGP: 4.28
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -3.96
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.71 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	3.70 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Aug. 13, 2009	FDA	FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anosognosia	1260.76	33.07	241	9314	2955	63476512
Blood prolactin abnormal	1257.18	33.07	239	9316	2840	63476627
Disturbance in social behaviour	1201.20	33.07	240	9315	3753	63475714
Sexual dysfunction	1174.28	33.07	239	9316	4120	63475347
Metabolic disorder	1073.47	33.07	238	9317	6265	63473202
Dystonia	1020.44	33.07	264	9291	13555	63465912
Personality change	1002.66	33.07	228	9327	6745	63472722
Sedation	911.99	33.07	305	9250	38504	63440963
Dyskinesia	858.23	33.07	278	9277	31724	63447743
Suicide attempt	635.70	33.07	264	9291	60654	63418813
Blood glucose increased	551.93	33.07	263	9292	83493	63395974
Inappropriate schedule of product administration	492.35	33.07	261	9294	103704	63375763
Hypoaesthesia oral	430.68	33.07	133	9422	12900	63466567
Underdose	415.79	33.07	156	9399	27300	63452167
Incorrect route of product administration	262.33	33.07	112	9443	27340	63452127
Akathisia	258.97	33.07	83	9472	9063	63470404
Insurance issue	166.91	33.07	54	9501	6067	63473400
Dysgeusia	129.23	33.07	83	9472	46627	63432840
Swollen tongue	114.35	33.07	69	9486	34731	63444736
Mania	97.13	33.07	44	9511	12323	63467144
Adverse drug reaction	93.71	33.07	85	9470	79629	63399838
Condition aggravated	85.30	33.07	187	9368	402030	63077437
Tooth discolouration	83.56	33.07	21	9534	947	63478520
Personality change due to a general medical condition	83.38	33.07	16	9539	198	63479269
Weight increased	76.55	33.07	139	9416	260653	63218814
Tardive dyskinesia	75.58	33.07	33	9522	8469	63470998
Extrapyramidal disorder	73.04	33.07	37	9518	13247	63466220
Suicidal ideation	62.65	33.07	61	9494	62360	63417107
Completed suicide	62.13	33.07	92	9463	145581	63333886
Diarrhoea	57.89	33.07	18	9537	715348	62764119
Restless legs syndrome	56.38	33.07	35	9520	18496	63460971
Fatigue	55.03	33.07	33	9522	887995	62591472
Drug ineffective	54.14	33.07	303	9252	1044462	62435005
Oral discomfort	51.66	33.07	26	9529	9175	63470292
Oropharyngeal blistering	50.94	33.07	14	9541	895	63478572
Tongue blistering	47.28	33.07	15	9540	1580	63477887
Arthralgia	44.86	33.07	15	9540	569695	62909772
Pain	43.78	33.07	29	9526	740599	62738868
Somnolence	43.41	33.07	88	9467	178597	63300870
Agitation	38.14	33.07	46	9509	59711	63419756
Asthenia	34.05	33.07	8	9547	383596	63095871

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	507.57	35.88	211	6368	38905	34911447
Akathisia	464.04	35.88	133	6446	7976	34942376
Antipsychotic drug level below therapeutic	387.51	35.88	91	6488	2456	34947896
Sedation	382.79	35.88	145	6434	20861	34929491
Therapeutic product effect variable	374.96	35.88	88	6491	2368	34947984
Disinhibition	371.16	35.88	92	6487	3134	34947218
Anosognosia	364.72	35.88	73	6506	900	34949452
Obsessive-compulsive disorder	344.03	35.88	97	6482	5467	34944885
Blood prolactin abnormal	335.18	35.88	68	6511	901	34949451
Increased appetite	324.86	35.88	99	6480	7330	34943022
Euphoric mood	320.19	35.88	92	6487	5549	34944803
Disturbance in social behaviour	291.33	35.88	68	6511	1783	34948569
Dystonia	280.27	35.88	97	6482	10748	34939604
Sexual dysfunction	241.77	35.88	76	6503	6227	34944125
Metabolic disorder	239.19	35.88	69	6510	4214	34946138
Emotional poverty	201.06	35.88	41	6538	557	34949795
Dyskinesia	199.49	35.88	93	6486	22320	34928032
Personality change	180.66	35.88	58	6521	5081	34945271
Weight increased	159.31	35.88	135	6444	92898	34857454
Therapeutic product effect incomplete	147.77	35.88	101	6478	50440	34899912
Inappropriate schedule of product administration	146.48	35.88	109	6470	62187	34888165
Leukaemia	145.74	35.88	48	6531	4555	34945797
Dyslipidaemia	119.40	35.88	47	6532	7441	34942911
Leukopenia	111.10	35.88	93	6486	62763	34887589
Extrapyramidal disorder	106.97	35.88	51	6528	12829	34937523
Hypoaesthesia oral	105.95	35.88	37	6542	4192	34946160
Underdose	103.69	35.88	51	6528	13729	34936623
Prescribed overdose	103.45	35.88	47	6532	10600	34939752
Obesity	97.91	35.88	48	6531	12830	34937522
Blood glucose increased	90.51	35.88	85	6494	66633	34883719
Drug ineffective	90.05	35.88	236	6343	456515	34493837
Toxicity to various agents	80.83	35.88	139	6440	200223	34750129
Incorrect route of product administration	80.22	35.88	44	6535	14801	34935551
Head titubation	80.20	35.88	18	6561	393	34949959
Cogwheel rigidity	76.40	35.88	22	6557	1330	34949022
Suicidal ideation	69.71	35.88	59	6520	40329	34910023
Mania	65.04	35.88	33	6546	9478	34940874
Sedation complication	62.19	35.88	20	6559	1757	34948595
Hallucination, auditory	55.37	35.88	32	6547	11885	34938467
Irritability	55.22	35.88	42	6537	24648	34925704
Schizoaffective disorder	55.02	35.88	17	6562	1310	34949042
Dysgeusia	54.74	35.88	43	6536	26454	34923898
Swollen tongue	51.84	35.88	33	6546	14572	34935780
Anticholinergic syndrome	43.25	35.88	14	6565	1255	34949097
Therapy non-responder	38.56	35.88	42	6537	39104	34911248
Insurance issue	36.75	35.88	14	6565	2025	34948327

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anosognosia	1487.47	28.88	282	11132	3482	79729492
Blood prolactin abnormal	1449.42	28.88	274	11140	3327	79729647
Disturbance in social behaviour	1367.30	28.88	275	11139	4695	79728279
Sexual dysfunction	1283.90	28.88	282	11132	7481	79725493
Metabolic disorder	1199.45	28.88	275	11139	8895	79724079
Dystonia	1119.28	28.88	308	11106	21091	79711883
Personality change	1118.66	28.88	265	11149	9905	79723069
Sedation	1101.15	28.88	373	11041	51522	79681452
Dyskinesia	965.87	28.88	326	11088	44447	79688527
Suicide attempt	916.69	28.88	369	11045	82563	79650411
Blood glucose increased	579.24	28.88	296	11118	114679	79618295
Inappropriate schedule of product administration	419.27	28.88	252	11162	133376	79599598
Underdose	319.14	28.88	134	11280	33017	79699957
Akathisia	306.74	28.88	102	11312	13157	79719817
Hypoaesthesia oral	277.01	28.88	96	11318	14028	79718946
Insurance issue	202.81	28.88	61	11353	5672	79727302
Emotional poverty	173.16	28.88	37	11377	850	79732124
Incorrect route of product administration	155.46	28.88	83	11331	34846	79698128
Adverse drug reaction	145.22	28.88	100	11314	66292	79666682
Drug ineffective	136.39	28.88	399	11015	1080514	78652460
Mania	103.24	28.88	51	11363	18209	79714765
Antipsychotic drug level below therapeutic	98.94	28.88	25	11389	1213	79731761
Increased appetite	97.34	28.88	43	11371	11935	79721039
Condition aggravated	95.89	28.88	217	11197	500907	79232067
Swollen tongue	95.12	28.88	65	11349	42505	79690469
Suicidal ideation	90.40	28.88	80	11334	76260	79656714
Extrapyramidal disorder	90.07	28.88	50	11364	22629	79710345
Therapeutic product effect variable	86.95	28.88	25	11389	1984	79730990
Disinhibition	84.83	28.88	26	11388	2572	79730402
Dysgeusia	75.95	28.88	64	11350	57113	79675861
Obsessive-compulsive disorder	70.79	28.88	28	11386	5899	79727075
Personality change due to a general medical condition	70.07	28.88	14	11400	228	79732746
Euphoric mood	60.41	28.88	27	11387	7699	79725275
Neuroleptic malignant syndrome	59.00	28.88	41	11373	27518	79705456
Tardive dyskinesia	58.19	28.88	29	11385	10542	79722432
Weight increased	57.23	28.88	124	11290	277262	79455712
Diarrhoea	56.33	28.88	28	11386	880461	78852513
Parkinsonism	56.27	28.88	33	11381	16551	79716423
Hallucination, auditory	51.98	28.88	34	11380	20659	79712315
Irritability	50.44	28.88	44	11370	41100	79691874
Dyslipidaemia	49.92	28.88	27	11387	11606	79721368
Completed suicide	48.56	28.88	108	11306	245659	79487315
Pneumonia	46.91	28.88	18	11396	660228	79072746
Fatigue	46.60	28.88	39	11375	929688	78803286
Anaemia	46.12	28.88	5	11409	445010	79287964
Arthralgia	41.59	28.88	15	11399	571788	79161186
Agitation	40.53	28.88	60	11354	99655	79633319
Schizoaffective disorder	39.75	28.88	14	11400	2138	79730836
Tooth discolouration	39.57	28.88	12	11402	1145	79731829
Cogwheel rigidity	34.83	28.88	14	11400	3074	79729900
Abdominal pain	34.34	28.88	7	11407	389562	79343412
Cataplexy	33.29	28.88	10	11404	924	79732050
Head titubation	33.24	28.88	10	11404	928	79732046
Product solubility abnormal	32.89	28.88	10	11404	962	79732012
Somnolence	32.39	28.88	91	11323	238890	79494084
Pharyngeal hypoaesthesia	32.05	28.88	8	11406	369	79732605
Oral discomfort	32.00	28.88	19	11395	9741	79723233
Drooling	31.83	28.88	16	11398	5918	79727056
Pain	31.11	28.88	33	11381	703769	79029205
Paranoia	30.52	28.88	24	11390	19408	79713566

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AH05	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines
FDA EPC	N0000175430	Atypical Antipsychotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35471	psychotropic drugs
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:65191	atypical antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Mixed bipolar I disorder	indication	16506000	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Bipolar affective disorder, current episode manic	indication	191618007
Depression Treatment Adjunct	off-label use
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Agranulocytosis	contraindication	17182001	DOID:12987
Lowered convulsive threshold	contraindication	19260006
Myocardial infarction	contraindication	22298006	DOID:5844
Alzheimer's disease	contraindication	26929004	DOID:10652
Hypovolemia	contraindication	28560003
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Dehydration	contraindication	34095006
Dysphagia	contraindication	40739000
Hypokalemia	contraindication	43339004
Bradycardia	contraindication	48867003
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Leukopenia	contraindication	84828003	DOID:615
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Hypomagnesemia	contraindication	190855004
Cerebrovascular accident	contraindication	230690007
Hyperprolactinemia	contraindication	237662005	DOID:12700
Transient ischemic attack	contraindication	266257000	DOID:224
Esophageal dysmotility	contraindication	266434009	DOID:9192
Syncope	contraindication	271594007
Neutropenic disorder	contraindication	303011007	DOID:1227
Senile dementia with psychosis	contraindication	371026009
At risk for aspiration	contraindication	371736008
Impaired cognition	contraindication	386806002
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.13	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 10MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 10MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 10MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 10MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
EQ 2.5MG BASE	SAPHRIS	ALLERGAN	N022117	March 12, 2015	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
EQ 2.5MG BASE	SAPHRIS	ALLERGAN	N022117	March 12, 2015	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
EQ 5MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 5MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 5MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 5MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 5MG BASE	SAPHRIS	ALLERGAN	N022117	Aug. 13, 2009	RX	TABLET	SUBLINGUAL	7741358	April 6, 2026	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
3.8MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10583121	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
3.8MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10814002	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10583121	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10814002	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10583121	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR	SECUADO	HISAMITSU	N212268	Oct. 11, 2019	RX	SYSTEM	TRANSDERMAL	10814002	July 25, 2033	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	9.61	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.75	WOMBAT-PK	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	8.70	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	8.19	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	7.97	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	9.80	WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	9.93	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	9.22	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	9.47	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.92	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.73	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	9.06	WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	7.64	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	9	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		IC50	8.21	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.11	PDSP
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.04	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.49	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.57	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	8.40	WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	8.40	IUPHAR
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.89	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.50	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	8.71	WOMBAT-PK
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.35	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	8.41	PDSP
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	8.60	WOMBAT-PK
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.30	PDSP
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN	AGONIST	Ki	8	IUPHAR
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	5.30	PDSP

External reference:

ID	Source
4029058	VUID
N0000179817	NUI
D02995	KEGG_DRUG
85650-56-2	SECONDARY_CAS_RN
4029058	VANDF
C2000088	UMLSCUI
CHEBI:71253	CHEBI
CHEMBL3187365	ChEMBL_ID
CHEMBL3544974	ChEMBL_ID
DB06216	DRUGBANK_ID
C522667	MESH_SUPPLEMENTAL_RECORD_UI
163091	PUBCHEM_CID
22	IUPHAR_LIGAND_ID
8278	INN_ID
JKZ19V908O	UNII
784649	RXNORM
167374	MMSL
26689	MMSL
341671	MMSL
d07473	MMSL
013233	NDDF
013234	NDDF
443374004	SNOMEDCT_US
443375003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0052-0118	TABLET	5 mg	SUBLINGUAL	NDA	33 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0052-0119	TABLET	10 mg	SUBLINGUAL	NDA	33 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0052-2139	TABLET	5 mg	SUBLINGUAL	NDA	33 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0052-2142	TABLET	10 mg	SUBLINGUAL	NDA	33 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2402	TABLET	2.50 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2402	TABLET	2.50 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2402	TABLET	2.50 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2405	TABLET	5 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2405	TABLET	5 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2405	TABLET	5 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2410	TABLET	10 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2410	TABLET	10 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2410	TABLET	10 mg	SUBLINGUAL	NDA	36 sections
SAPHRIS	HUMAN PRESCRIPTION DRUG LABEL	1	16590-936	TABLET	10 mg	SUBLINGUAL	NDA	34 sections
ASENAPINE	HUMAN PRESCRIPTION DRUG LABEL	1	42794-016	TABLET	5 mg	SUBLINGUAL	ANDA	21 sections
ASENAPINE	HUMAN PRESCRIPTION DRUG LABEL	1	42794-016	TABLET	5 mg	SUBLINGUAL	ANDA	21 sections
ASENAPINE	HUMAN PRESCRIPTION DRUG LABEL	1	42794-017	TABLET	10 mg	SUBLINGUAL	ANDA	21 sections
ASENAPINE	HUMAN PRESCRIPTION DRUG LABEL	1	42794-017	TABLET	10 mg	SUBLINGUAL	ANDA	21 sections
Asenapine	Human Prescription Drug Label	1	46708-198	TABLET	5 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	Human Prescription Drug Label	1	46708-198	TABLET	5 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	Human Prescription Drug Label	1	46708-199	TABLET	10 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	Human Prescription Drug Label	1	46708-199	TABLET	10 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	Human Prescription Drug Label	1	46708-544	TABLET	2.50 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	Human Prescription Drug Label	1	46708-544	TABLET	2.50 mg	SUBLINGUAL	ANDA	29 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-358	TABLET	5 mg	SUBLINGUAL	ANDA	36 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-359	TABLET	5 mg	SUBLINGUAL	ANDA	36 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-360	TABLET	10 mg	SUBLINGUAL	ANDA	36 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-361	TABLET	10 mg	SUBLINGUAL	ANDA	36 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-928	TABLET	2.50 mg	SUBLINGUAL	ANDA	36 sections
Asenapine	HUMAN PRESCRIPTION DRUG LABEL	1	59762-1091	TABLET	2.50 mg	SUBLINGUAL	NDA AUTHORIZED GENERIC	35 sections